Placental transfer of intravenous nicardipine and disposition into breast milk during the control of hypertension in women with pre-eclampsia

Hypertens Pregnancy. 2014 Feb;33(1):93-101. doi: 10.3109/10641955.2013.846367. Epub 2013 Oct 16.

Abstract

Objective: To assess nicardipine safety for fetuses and neonates.

Methods: Nicardipine was measured in maternal plasma (MP), umbilical cord arterial (UaP) and venous (UvP) plasma and breast milk (BrM) of 18 women with severe preeclampsia.

Results: Nicardipine was infused for a mean 11.9 ± 10.5 days before and 4.6 ± 1.6 days after delivery. Nicardipine dose and MP concentration were linearly correlated, as were MP with UaP, UvP, and BrM concentrations. The BrM/MP ratio was 0.06 to 0.30. The mean relative infant dose was 0.082%.

Conclusion: Nicardipine is safe for fetuses and neonates due to its low levels of placental transfer and disposition in BrM.

MeSH terms

  • Adult
  • Antihypertensive Agents / blood
  • Antihypertensive Agents / pharmacokinetics*
  • Antihypertensive Agents / therapeutic use
  • Female
  • Fetal Blood / chemistry
  • Humans
  • Infant, Newborn
  • Milk, Human / chemistry*
  • Nicardipine / blood
  • Nicardipine / pharmacokinetics*
  • Nicardipine / therapeutic use
  • Placenta / metabolism*
  • Pre-Eclampsia / drug therapy*
  • Pregnancy

Substances

  • Antihypertensive Agents
  • Nicardipine